| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
PC-190723 targets FtsZ, a bacterial cell division protein that polymerizes and assembles into a ring (Z-ring) to initiate cell division. By inhibiting FtsZ, PC-190723 disrupts Z-ring formation and prevents bacterial cell division, leading to filamentation and ultimately cell lysis. It is a selective benzamide-derived inhibitor of FtsZ.
|
|---|---|
| ln Vitro |
In vitro, PC-190723 demonstrates potent antibacterial activity against S. aureus, including methicillin-resistant (MRSA) and multi-drug-resistant strains. It inhibits FtsZ polymerization and GTPase activity. Specific MIC values against various S. aureus strains have been reported, though exact numbers are not detailed in the available results.
|
| ln Vivo |
In vivo, PC-190723 has shown efficacy in animal models of S. aureus infection. Its effectiveness against methicillin- and multi-drug-resistant strains makes it a promising lead compound for the development of new antibiotics to combat drug-resistant bacterial infections. Specific in vivo study details are limited in the available literature.
|
| Enzyme Assay |
FtsZ GTPase activity is measured using biochemical assays with purified FtsZ protein and GTP as substrate. GTP hydrolysis is quantified by measuring inorganic phosphate release using colorimetric assays (e.g., malachite green). FtsZ polymerization is assessed by light scattering or electron microscopy. PC-190723 is tested at various concentrations to determine IC₅₀ values.
|
| Cell Assay |
S. aureus cells are cultured in appropriate media (e.g., Mueller-Hinton broth) at 37°C. Antibacterial susceptibility testing is performed using broth microdilution or agar dilution methods following CLSI guidelines. PC-190723 is tested at various concentrations, and MIC values are determined after 18-24 h incubation.
|
| Animal Protocol |
In vivo efficacy is evaluated in murine models of S. aureus infection (e.g., systemic infection, skin and soft tissue infection, pneumonia). PC-190723 is administered intraperitoneally or orally. Endpoints include survival rates, bacterial load in tissues, and histopathological assessment. Pharmacokinetic studies may be conducted to support efficacy studies.
|
| ADME/Pharmacokinetics |
PC-190723 has a molecular weight of approximately 355.0 and a density of 1.6±0.1 g/cm³. It has a boiling point of 462.3±45.0 °C at 760 mmHg. Specific pharmacokinetic parameters (half-life, bioavailability) are not extensively documented in the available literature.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for PC-190723 are not extensively documented in the available literature. As a novel antibacterial agent, its safety profile is still being characterized. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
PC-190723 is a selective benzamide-derived FtsZ inhibitor with potent activity against MRSA and MDRSA. It represents a promising new class of antibacterial agents targeting bacterial cell division, which is distinct from clinically used antibiotics. Its development addresses the urgent need for new antibiotics to combat drug-resistant bacterial infections.
|
| Molecular Formula |
C14H8CLF2N3O2S
|
|---|---|
| Molecular Weight |
355.7438
|
| Exact Mass |
354.999
|
| CAS # |
951120-33-5
|
| PubChem CID |
25016417
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
4.001
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
23
|
| Complexity |
450
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1C(F)=C(OCC2SC3C(=CC(=CN=3)Cl)N=2)C=CC=1F)N
|
| InChi Key |
INYJNSBDHOVLAH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H8ClF2N3O2S/c15-6-3-8-14(19-4-6)23-10(20-8)5-22-9-2-1-7(16)11(12(9)17)13(18)21/h1-4H,5H2,(H2,18,21)
|
| Chemical Name |
3-[(6-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl)methoxy]-2,6-difluorobenzamide
|
| Synonyms |
PC 190723 PC190723 PC-190723
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~200 mg/mL (~562.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (14.05 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (14.05 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 5 mg/mL (14.05 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8110 mL | 14.0552 mL | 28.1104 mL | |
| 5 mM | 0.5622 mL | 2.8110 mL | 5.6221 mL | |
| 10 mM | 0.2811 mL | 1.4055 mL | 2.8110 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
